Inozyme Pharma (NASDAQ:INZY) Releases Earnings Results, Beats Estimates By $0.05 EPS

Inozyme Pharma (NASDAQ:INZY) posted its quarterly earnings results on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05, Zacks reports.

Inozyme Pharma Stock Down 0.9 %

Shares of INZY stock traded down $0.04 during trading on Thursday, hitting $4.19. 218,480 shares of the company were exchanged, compared to its average volume of 417,269. The company has a debt-to-equity ratio of 0.48, a quick ratio of 9.84 and a current ratio of 9.84. The firm has a market capitalization of $262.84 million, a price-to-earnings ratio of -2.90 and a beta of 1.54. The business’s 50-day simple moving average is $5.15 and its 200 day simple moving average is $4.93. Inozyme Pharma has a twelve month low of $2.71 and a twelve month high of $7.80.

Wall Street Analysts Forecast Growth

INZY has been the topic of several recent research reports. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday. Wedbush reissued an “outperform” rating and set a $12.00 target price (down previously from $15.00) on shares of Inozyme Pharma in a research note on Tuesday. Finally, Jefferies Financial Group reissued a “buy” rating and set a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inozyme Pharma presently has an average rating of “Buy” and an average target price of $15.71.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.